Takeshi Kitai1, Yong-Hyun Kim1, Kathryn Kiefer2, Rommel Morales2, Allen G Borowski1, Justin L Grodin3, W H Wilson Tang4. 1. Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, United States. 2. Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland, OH, United States. 3. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States. 4. Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, United States; Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland, OH, United States. Electronic address: tangw@ccf.org.
Abstract
BACKGROUND: Venous congestion has become increasingly recognized as a potential contributor to end-organ dysfunction in heart failure. Elevated I-FABP, which is excreted specifically from damaged intestinal epithelial cells, has been found in patients with abdominal hypertension and intestinal ischemia. We hypothesize that elevated intestinal fatty acid-binding protein (I-FABP) levels would identify patients with more advanced heart failure who have venous and intestinal congestion. METHODS: Baseline serum I-FABP levels were measured in 69 acute decompensated heart failure (ADHF) patients admitted to the intensive care unit for invasive hemodynamic monitoring and tailored medical therapy. Comprehensive echocardiography examinations were performed in all study patients, and clinical outcomes (death, cardiac transplant or left ventricular assist device placement) were assessed. RESULTS: The median circulating I-FABP level was 853pg/ml (interquartile range: 533 to 1448pg/ml). Age, gender, race, and baseline comorbidities were comparable between patients with low and high I-FABP levels. Although there were no significant correlations between I-FABP levels and invasively-measured hemodynamic parameters nor echocardiographic parameters, patients with higher I-FABP levels (≥853g/ml) had significantly worse clinical outcomes compared to those with lower I-FABP levels (<853pg/ml, P=0.025). CONCLUSION: Circulating I-FABP levels had no association with invasively-measured hemodynamic parameters, but were associated with adverse clinical outcomes in patients with ADHF with systolic dysfunction.
BACKGROUND:Venous congestion has become increasingly recognized as a potential contributor to end-organ dysfunction in heart failure. Elevated I-FABP, which is excreted specifically from damaged intestinal epithelial cells, has been found in patients with abdominal hypertension and intestinal ischemia. We hypothesize that elevated intestinal fatty acid-binding protein (I-FABP) levels would identify patients with more advanced heart failure who have venous and intestinal congestion. METHODS: Baseline serum I-FABP levels were measured in 69 acute decompensated heart failure (ADHF) patients admitted to the intensive care unit for invasive hemodynamic monitoring and tailored medical therapy. Comprehensive echocardiography examinations were performed in all study patients, and clinical outcomes (death, cardiac transplant or left ventricular assist device placement) were assessed. RESULTS: The median circulating I-FABP level was 853pg/ml (interquartile range: 533 to 1448pg/ml). Age, gender, race, and baseline comorbidities were comparable between patients with low and high I-FABP levels. Although there were no significant correlations between I-FABP levels and invasively-measured hemodynamic parameters nor echocardiographic parameters, patients with higher I-FABP levels (≥853g/ml) had significantly worse clinical outcomes compared to those with lower I-FABP levels (<853pg/ml, P=0.025). CONCLUSION: Circulating I-FABP levels had no association with invasively-measured hemodynamic parameters, but were associated with adverse clinical outcomes in patients with ADHF with systolic dysfunction.
Authors: David Verhaert; Wilfried Mullens; Allen Borowski; Zoran B Popović; Ronan J Curtin; James D Thomas; W H Wilson Tang Journal: Circ Heart Fail Date: 2010-02-22 Impact factor: 8.790
Authors: F H Heida; J B F Hulscher; M Schurink; A Timmer; E M W Kooi; A F Bos; J L M Bruggink; D C Kasper; M Pones; T Benkoe Journal: J Pediatr Surg Date: 2014-11-21 Impact factor: 2.545
Authors: Wilfried Mullens; Zuheir Abrahams; Gary S Francis; Hadi N Skouri; Randall C Starling; James B Young; David O Taylor; W H Wilson Tang Journal: J Am Coll Cardiol Date: 2008-07-15 Impact factor: 24.094
Authors: Anja Sandek; Juergen Bauditz; Alexander Swidsinski; Sabine Buhner; Jutta Weber-Eibel; Stephan von Haehling; Wieland Schroedl; Tim Karhausen; Wolfram Doehner; Mathias Rauchhaus; Philip Poole-Wilson; Hans-Dieter Volk; Herbert Lochs; Stefan D Anker Journal: J Am Coll Cardiol Date: 2007-10-01 Impact factor: 24.094
Authors: Jean-Louis Vincent; Paolo Pelosi; Rupert Pearse; Didier Payen; Azriel Perel; Andreas Hoeft; Stefano Romagnoli; V Marco Ranieri; Carole Ichai; Patrice Forget; Giorgio Della Rocca; Andrew Rhodes Journal: Crit Care Date: 2015-05-08 Impact factor: 9.097
Authors: Lediya T Cheru; Elli A Park; Charles F Saylor; Tricia H Burdo; Kathleen V Fitch; Sara Looby; Jeffrey Weiner; Jake A Robinson; Jane Hubbard; Martin Torriani; Janet Lo Journal: Open Forum Infect Dis Date: 2018-11-05 Impact factor: 3.835